A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion

Launched by TAKEDA · Dec 20, 2022

Keywords

ClinConnect Summary

This clinical trial is designed to understand how well patients with Gaucher disease, their caregivers, and nurses understand and use educational materials related to a treatment called VPRIV, which is given at home. The educational materials include an infusion diary to help track treatments and an emergency plan for any issues that might arise during the infusion process. The survey will be conducted in various European countries and will gather information through questionnaires that can be filled out either on paper or electronically.

To participate in this survey, you need to be a patient with Gaucher disease receiving VPRIV at home, a caregiver assisting that patient, or a nurse who administers this treatment at home. However, individuals who work for regulatory bodies or the pharmaceutical industry cannot take part due to potential conflicts of interest. Once the survey starts, participants can expect to answer questions about how they use and understand the educational materials provided for VPRIV treatment. This information will help improve support and resources for everyone involved in managing Gaucher disease at home.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Gaucher disease participants who receive VPRIV® for home infusion and their caregivers.
• • 2. Home infusion nurses administering VPRIV® to participants with Gaucher disease at home.
• Exclusion criteria:
• • Potential respondents will be excluded if they have conflicts of interest with the survey (e.g., if they are employed by regulatory bodies, or pharmaceutical industry).